the Web site devoted to the study of the glucagon-like peptides
This Web site is maintained by Dr. Daniel J. Drucker, Mount Sinai Hospital Samuel Lunenfeld Research Institute University of Toronto
Exenatide once weekly approved in the United States January 27 2012
Remitting seronegativesymmetrical synovitis with pitting edema (RS3PE) and clinical use of DPP-4 inhibitors DPP-4 and immune function
GLP-1R activation and preneoplastic foci in rodent models of pancreatic cancer GLP-1 Adverse Events
Reduction of cardiovascular DPP-4 activity and increased microvascular coagulation DPP-4 and the Cardiovascular System
Glp2r-/- mice exhibit defective Paneth cell function and enhanced sensitivity to small bowel injury Essential GLP-2 action: Studies with antagonists
For updates to glucagon.com, Follow us on Twitter DanielJDrucker
